Company Chats
Monday, june 15
NASDAQ: AREC
Mark C. Jensen
Chief Executive Officer and Chairman of Board
American Resources is a supplier of high-quality raw materials to the rapidly growing global infrastructure market. The Company is focused on the extraction
and processing of metallurgical carbon, an essential ingredient used in steelmaking.
MONday, june 15
OTCQB: ARTH
Terrence Norchi, MD
Chairman of the Board of Directors, President and Chief Executive Officer
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Topical Gel, AC5 Topical Hemostat and AC5 Surgical Hemostat.
MONday, june 15
Tuesday, JUNE 16
Leveraging proprietary neurodegenerative disease platform and growing body of compelling data to advance the first potential approved treatment for Huntington’s disease
NASDAQ: VCNX
Maurice Zauderer, Ph.D.
President and Chief Executive Officer
Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.
Chat Replay
Tuesday, JUNE 16
A Targeted Approach to CAR T Cell Therapy
NASDAQ: XBIO
Jeffrey F. Eisenberg
Chief Executive Officer
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Tuesday, JUNE 16
NYSE American: NAVB
Jed A. Latkin
Chief Executive Officer, Chief Financial Officer
and Chief Operating Officer
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
Wednesday, JUNE 17
De-Risked Base Business, Broad Utility Platform Technologies, and Innovative Business Model
TSX-V: CZO;
OTCQX: CRPOF
Gilles Gagnon, M.Sc., MBA
President and Chief Executive Officer
Ceapro Inc. is a biotechnology company involved in the development & commercialization of “active ingredients” derived from oats & other renewable plant resources for healthcare and cosmetic industries utilizing its proprietary extraction technology.
WEDNESday, JUNE 17
Innovating game improvement equipment for all ball sports, with an initial focus on the global tennis market with the Slinger Bag - the most portable tennis ball launcher ever
![Mike Ballardie Headshot[3].jpg](https://static.wixstatic.com/media/094bb2_0c749ac8d51c484aae960ddb4d444d05~mv2.jpg/v1/crop/x_21,y_0,w_157,h_200/fill/w_110,h_140,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/Mike%20Ballardie%20Headshot%5B3%5D.jpg)
OTC: SLBG
Mike Ballardie
Chief Executive Officer
Slinger® is a new sports brand focused on delivering innovative, game improvement technologies and equipment across all Ball Sport categories. With the vision to become a next-generation sports consumer products company, Slinger® enhances the skill and enjoyment levels of players of all ages and abilities.
WEDNESDAY, JUNE 17
Innovative use of a streamlined regulatory pathway for the first ophthalmic formulation of bevacizumab for treating retinal diseases
NASDAQ: OTLK
Lawrence A. Kenyon
President, Chief Executive Officer and Chief Financial Officer
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab (LYTENAVA™ or bevacizumab-vikg), for use in retinal indications, including wet AMD, DME and BRVO.
© 2020 Virtual Investor All rights reserved.
NASDAQ: MOTS
Timothy P. Moran
Chief Executive Officer, Director
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s flagship product is the Pure-Vu®System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques.